zanamivir
Term · Oncology and biomedicine · MLC-T-ONC-009457
A drug used to prevent and to treat influenza virus infections. It blocks the release of the virus from infected cells. It is a type of antiviral agent. Also called Relenza.
A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication.
| Identifier | MLC-T-ONC-009457 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Relenza |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009457",
"term": "zanamivir",
"field": "Oncology and biomedicine",
"definitions": [
"A drug used to prevent and to treat influenza virus infections. It blocks the release of the virus from infected cells. It is a type of antiviral agent. Also called Relenza.",
"A sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication."
],
"synonyms": [
"Relenza"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/zanamivir/"
}
Record 17,597 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.